Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to stall endometrial cancer in High-Risk patients

NCT ID NCT06366347

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if this maintenance therapy extends the time before the cancer progresses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinosarcoma of the corpus uteri endometrial cancer endometrial carcinoma endometrial endometrioid adenocarcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER RECURRENT ENDOMETRIAL CANCER TP53

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute at Foxborough

    WITHDRAWN

    Foxborough, Massachusetts, 02035, United States

  • Dana-Farber Cancer Institute at Milford

    WITHDRAWN

    Milford, Massachusetts, 01757, United States

  • Dana-Farber Cancer Institute at South Shore Hospital

    RECRUITING

    Weymouth, Massachusetts, 02190, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.